You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
日本藥業巨擘參戰新冠藥物開發 鹽野義展開臨牀試驗
阿思達克 07-26 12:05
據《華爾街日報》報道,繼輝瑞(PFE.US)及默克(MRK.US)展開新冠肺炎治療方法開發後,日本鹽野義製藥已於本月展開對首款每日只需服用一次的新冠肺炎藥片進行臨牀試驗,試驗可能持續到明年。

鹽野義製藥比輝瑞和默克公司晚了幾個月,後兩者已經開始對新冠藥物進行中後期試驗。輝瑞表示,該公司每日服用兩次的藥片可能最快今年可投入市場。該公司正準備招募2,000多名患者,進行該抗病毒藥物與一款作爲增強劑的抗病毒藥物聯合使用的試驗,使用安慰劑做爲對照組。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account